Cargando…
Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial
BACKGROUND: Although traditional wound dressings such as collagen scaffolds promote granulation tissue formation, the efficacy of these dressings in chronic wounds is limited because of high susceptibility to bacterial growth. Biomaterials that can be applied to chronic wounds should have an anti-ba...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081464/ https://www.ncbi.nlm.nih.gov/pubmed/33936917 http://dx.doi.org/10.1097/GOX.0000000000003556 |
_version_ | 1783685645316653056 |
---|---|
author | Noda, Kazuo Kawai, Katsuya Matsuura, Yoshitaka Ito-Ihara, Toshiko Amino, Yoko Ushimaru, Mika Kinoshita, Akemi Tada, Harue Abe, Hiroyasu Morita, Satoshi Shimizu, Akira Tsuge, Itaru Sakamoto, Michiharu Morimoto, Naoki |
author_facet | Noda, Kazuo Kawai, Katsuya Matsuura, Yoshitaka Ito-Ihara, Toshiko Amino, Yoko Ushimaru, Mika Kinoshita, Akemi Tada, Harue Abe, Hiroyasu Morita, Satoshi Shimizu, Akira Tsuge, Itaru Sakamoto, Michiharu Morimoto, Naoki |
author_sort | Noda, Kazuo |
collection | PubMed |
description | BACKGROUND: Although traditional wound dressings such as collagen scaffolds promote granulation tissue formation, the efficacy of these dressings in chronic wounds is limited because of high susceptibility to bacterial growth. Biomaterials that can be applied to chronic wounds should have an anti-bacterial function. We previously reported that administering a silk-elastin solution that forms moisturizing hydrogels to wound surfaces of diabetic mice reduced bacterial growth and promoted granulation tissue formation compared with control or carboxymethyl cellulose hydrogels. We hypothesized that silk-elastin promotes wound healing in human chronic wounds by suppressing bacterial growth. METHODS: An open-label, clinical case series was conducted with a prospective, single-arm design at Kyoto University Hospital in Kyoto, Japan. In this study, 6 patients with chronic skin ulcers of any origin (2 < ulcer area (cm(2)) < 25) on their lower extremities were included; patients with critical ischemia were excluded. Silk-elastin sponges were applied and covered with a polyurethane film without changing the dressing for 14 days. Inflammation triggered treatment discontinuation due to fear of infection. The primary study endpoint was adverse events, including inflammation and infection. RESULTS: Poor hydrogel formation, possibly due to continuous exudation, was observed. No serious adverse events were noted. Two patients discontinued treatment on day 6 and day 7, respectively, due to inflammation, but they were not infected. The other 4 patients completed the 14-day silk-elastin sponge treatment without infection. CONCLUSION: Silk-elastin sponge is safe for chronic skin ulcers, and its ability to promote wound healing should be determined by confirmatory clinical trials. |
format | Online Article Text |
id | pubmed-8081464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-80814642021-04-30 Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial Noda, Kazuo Kawai, Katsuya Matsuura, Yoshitaka Ito-Ihara, Toshiko Amino, Yoko Ushimaru, Mika Kinoshita, Akemi Tada, Harue Abe, Hiroyasu Morita, Satoshi Shimizu, Akira Tsuge, Itaru Sakamoto, Michiharu Morimoto, Naoki Plast Reconstr Surg Glob Open Reconstructive BACKGROUND: Although traditional wound dressings such as collagen scaffolds promote granulation tissue formation, the efficacy of these dressings in chronic wounds is limited because of high susceptibility to bacterial growth. Biomaterials that can be applied to chronic wounds should have an anti-bacterial function. We previously reported that administering a silk-elastin solution that forms moisturizing hydrogels to wound surfaces of diabetic mice reduced bacterial growth and promoted granulation tissue formation compared with control or carboxymethyl cellulose hydrogels. We hypothesized that silk-elastin promotes wound healing in human chronic wounds by suppressing bacterial growth. METHODS: An open-label, clinical case series was conducted with a prospective, single-arm design at Kyoto University Hospital in Kyoto, Japan. In this study, 6 patients with chronic skin ulcers of any origin (2 < ulcer area (cm(2)) < 25) on their lower extremities were included; patients with critical ischemia were excluded. Silk-elastin sponges were applied and covered with a polyurethane film without changing the dressing for 14 days. Inflammation triggered treatment discontinuation due to fear of infection. The primary study endpoint was adverse events, including inflammation and infection. RESULTS: Poor hydrogel formation, possibly due to continuous exudation, was observed. No serious adverse events were noted. Two patients discontinued treatment on day 6 and day 7, respectively, due to inflammation, but they were not infected. The other 4 patients completed the 14-day silk-elastin sponge treatment without infection. CONCLUSION: Silk-elastin sponge is safe for chronic skin ulcers, and its ability to promote wound healing should be determined by confirmatory clinical trials. Lippincott Williams & Wilkins 2021-04-28 /pmc/articles/PMC8081464/ /pubmed/33936917 http://dx.doi.org/10.1097/GOX.0000000000003556 Text en Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Reconstructive Noda, Kazuo Kawai, Katsuya Matsuura, Yoshitaka Ito-Ihara, Toshiko Amino, Yoko Ushimaru, Mika Kinoshita, Akemi Tada, Harue Abe, Hiroyasu Morita, Satoshi Shimizu, Akira Tsuge, Itaru Sakamoto, Michiharu Morimoto, Naoki Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial |
title | Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial |
title_full | Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial |
title_fullStr | Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial |
title_full_unstemmed | Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial |
title_short | Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial |
title_sort | safety of silk-elastin sponges in patients with chronic skin ulcers: a phase i/ii, single-center, open-label, single-arm clinical trial |
topic | Reconstructive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081464/ https://www.ncbi.nlm.nih.gov/pubmed/33936917 http://dx.doi.org/10.1097/GOX.0000000000003556 |
work_keys_str_mv | AT nodakazuo safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT kawaikatsuya safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT matsuurayoshitaka safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT itoiharatoshiko safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT aminoyoko safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT ushimarumika safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT kinoshitaakemi safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT tadaharue safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT abehiroyasu safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT moritasatoshi safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT shimizuakira safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT tsugeitaru safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT sakamotomichiharu safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial AT morimotonaoki safetyofsilkelastinspongesinpatientswithchronicskinulcersaphaseiiisinglecenteropenlabelsinglearmclinicaltrial |